SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor upcoming FDA action on the cemdisiran application, expected within 10-12 months of submission. The combination of best-in-class efficacy, durable response, and convenient dosing could drive rapid adoption and premium pricing. Investors should also watch for updates on combination trials with pozelimab in PNH and geographic atrophy.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$747.15
T+0 close · Apr 21, 2026 · via day close
Latest settled
−9.13%
T+60 · $678.94
Vs SPY
−15.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $747.15entry
  2. T+1 · 7mo ago −0.11%α −1.13% · $746.32
  3. T+5 · 7mo ago −2.38%α −3.46% · $729.36
  4. T+20 · 6mo ago −15.72%α −20.64% · $629.68
  5. T+60 · 4mo ago −9.13%α −15.75% · $678.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG), demonstrating statistically significant and clinically meaningful improvements in both primary and key secondary endpoints. The company has submitted a U.S. regulatory application and plans European filings in 2026, positioning cemdisiran as a potential first-in-class siRNA treatment for gMG with convenient quarterly dosing.

Key Facts

  • Cemdisiran met primary endpoint with a 2.3-point placebo-adjusted improvement in MG-ADL score at week 24 (p<0.001)
  • Achieved key secondary endpoint with a 2.8-point placebo-adjusted improvement in QMG score (p=0.002)
  • 76.6% of cemdisiran patients had ≥3-point improvement in MG-ADL vs. 44.1% on placebo
  • 48.4% of cemdisiran patients had ≥5-point improvement in QMG vs. 19% on placebo
  • U.S. regulatory application submitted in Q1 2026; EU filings planned for 2026
  • Cemdisiran is a novel siRNA therapeutic allowing for every-three-month subcutaneous dosing

Financial Impact

Potential blockbuster revenue opportunity; gMG affects ~85,000 people in the U.S. with high unmet need

revenuepipeline valueR&D efficiency

Risk Factors

  • Regulatory delay or rejection despite positive data
  • Safety concerns related to complement inhibition (e.g., infection risk), particularly given the boxed warning for related drug Veopoz
  • Competition from existing C5 inhibitors with established efficacy and safety profiles

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278163

Track record

53 reports on REGN

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026